Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Diabetes World Drug Market Report 2016-2026


News provided by

Visiongain Ltd

05 Jul, 2016, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, July 4, 2016 /PRNewswire/ --

- Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

- Treating Diabetes - Benefit Your Influence by Finding New R&D Trends and Sales Prospects

Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.

Visiongain's updated report forecasts those revenues to 2026 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what's possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines' predicted revenue.

Forecasts to 2026 and other analyses explain and predict the diabetes treatment market
Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2026, also with recent results, growth rates, market shares and discussions.

Our 258 page report provides 76 tables and 141 figures, and an interview with Professor Mark Baker, Director of the Centre for Clinical Practice (CCP) at the National Institute of Healthcare Excellence.

Our work's purpose is to predict that industry's future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.

The following sections show how our new investigation benefits your work.

Forecasting of the world diabetes drugs market and its segments - what does the future hold?
What are the secrets of the industry's progress? Where's it heading? Discover in our report overall world revenue prediction to 2026 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2026 for nine therapeutic submarkets at world level:
• Human insulins and analogues
• Dipeptidyl peptidase-4 inhibitors (DPP-4)
• Biguanides
• Glucagon-like peptide-1 receptor agonists (GLP-1)
• Sulfonylureas.

And these treatment categories:
• Thiazolidinediones
• Alpha-glucosidase inhibitors
• Meglitinides
• Sodium-glucose co-transporter-2 inhibitors (SGLT2)
• Other agents (grouped).

You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2016-2026. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.

Also you will find top medicines' revenue potentials.

Predictions of leading products' sales - see what's possible, and where you can gain
How will individual drugs for elevated blood sugar perform to 2026 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
• Lantus
• Januvia
• NovoLog and NovoMix
• Levemir
• Humalog
• Victoza
• Janumet
• Humulin.

There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what's happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

Our work also gives geographical sales predictions.

National markets - what is the outlook for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2016 to 2026. See where, how and what's possible.

Our analyses show you individual revenue forecasts to 2026 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations - Brazil, Russia, India and China.

There you can explore the market progress, needs and opportunities. What events will change that market and the outlook for payers and patients? Our work shows you, discussing the trends and demands.

Events affecting developers, producers and sellers of those metabolic treatments
Our report also explains issues, forces and events affecting the antidiabetics industry and market from 2016, including these influences:
• Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
• Governmental investment and collaboration between pharmaceutical companies
• Combination therapies for type 2 diabetes
• Competition from biosimilars and generic drugs - approvals and product launches.

And these issues are also assessed, among others:
• Disease incidence and prevalence
• Risk factors - obesity and pre-diabetes, related metabolic conditions
• Drug delivery - technologies for introducing insulin and oral drugs
• New classes of antidiabetic medications and regulatory challenges
• Type 1 diabetes vaccine - new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you can investigate what stimulates and restrains that biopharma, affecting its results. Also you will see the prospects for small-molecule therapies.

Analysis of firms and potential for rising sales - what overall revenues are possible?
What happens next? Our study predicts the world market will rise to $75bn in 2020, with high, expanding revenues from 2016 to 2026. Discover what's possible.

Our analysis covers organisations shaping that industry:
• Novo Nordisk
• Eli Lilly
• Novartis
• AstraZeneca
• Merck & Co.

We also investigate these leading companies, among other firms, including specialists in metabolic disorders:
• Boehringer Ingelheim
• Takeda
• Sanofi
• Bayer
• Pfizer.

From 2016, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

Ways Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2016-2026 helps
In particular, our new investigation gives this knowledge to benefit your work:
• Antidiabetic drug revenues to 2026 at overall world level, for 9 therapeutic submarkets and 31 products - assess outlooks for production, marketing and sales
• Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for demand and revenue potentials
• Prospects for established competitors, rising companies and new entrants - explore portfolios, opinions, results, strategies, technologies and outlooks for success
• Review of R&D pipelines - examine progress in research and development, finding technological and medical prospects
• Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete, gain advantages and succeed.

Our new study, produced in-house by our UK-based analysts, helps your knowledge and authority.

Companies and Organisations Mentioned 

   
    Actavis
    Alphapharm
    American Diabetes Association
    Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
    Andromeda Biotech
    Arisaph
    Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
    Astellas Pharma
    AstraZeneca
    Bayer
    Biocon
    Blue Cross
    Bristol-Myers Squibb
    Biogen Idec
    Boehringer Ingelheim
    Boston Therapeutics
    Chugai Pharmaceutical
    Diabetes UK
    DiaMedica
    Diamyd Medical
    Eisai
    Eli Lilly
    European Medicines Agency (EMA)
    Express Scripts
    Food and Drug Administration (US FDA)
    Franco-Indian Pharmaceuticals
    Furiex Pharmaceuticals
    Genentech
    Generex Biotechnology Corporation
    GlaxoSmithKline (GSK)
    Glenmark Pharmaceuticals
    Google
    Human Genome Sciences
    Intarcia
    International Diabetes Federation (IDF)
    Janssen (subsidiary of J&J)
    Johnson & Johnson (J&J)
    Lupin
    Kissei Pharmaceuticals
    Kotobuki Pharma
    Kowa
    MannKind Corporation
    Mascot Health Series
    Merck & Co.
    Merck Serono
    Ministry of Health (MoH, Germany)
    Ministry of Health, Labour and Welfare (MHLW, Japan)
    MSD KK (Asian subsidiary of Merck & Co.)
    Mylan
    National Health Service (NHS, UK)
    National Institute of Health and Clinical Excellence (NICE, UK)
    Novartis
    Novo Nordisk
    Ono Pharmaceuticals
    Oramed Pharmaceuticals
    Patheon
    Pfizer
    Ranbaxy Laboratories
    Roche
    Salix Pharmaceuticals
    Sandoz
    Sanofi
    Santarus (bought by Salix Pharmaceuticals)
    Servier
    Shantha Biotechnics (acquired by Sanofi)
    Shionogi Pharmaceuticals
    Shreya Life Sciences
    Stanford University School of Medicine
    Sun Pharma
    Takeda
    Taisho Pharmaceutical
    Teva Pharmaceutical Industries
    Theracos
    Transdermal Specialities
    United States Diabetes Prevention Program (DPP)
    World Health Organization (WHO)
    Yabao Pharmaceutical
    Zydus Cadila

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1676/Diabetes-World-Drug-Market-Report-2016-2026

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.